Recent evidence indicates that inhibition of histone acetyltransferases may be a primary cause of cellular pathogenesis in polyglutamine diseases such as Huntington disease; the results raise the possibility that pharmacologic manipulation of protein acetylation levels could be of therapeutic benefit.
Nine fatal neurodegenerative diseases are known to be caused by mutation in polyglutamine-encoding CAG tracts. These include Huntington disease, Kennedy disease (SBMA), six spinocerebellar ataxias (SCAs) and dentatorubral pallidoluysian atrophy [1] . The lengths of CAG tracts in genes susceptible to expansion are polymorphic in the unaffected population. In the Huntington disease gene, the 'normal' range is 6 to 34 CAGs. In general, it appears that tracts of 37 or more CAGs cross a pathogenic threshold, acquiring a propensity to further expansion and encoding proteins with neurotoxic activity [2] .
There is general agreement that a root cause of polyglutamine disease is interference by expanded polyglutamine (polyQ) tracts in cellular pathways. This pathogenic mechanism likely involves aberrant interactions between expanded polyQ regions and essential cellular proteins. But we are only beginning to understand in molecular detail the nature, number and relative importance of these polyQ-sensitive pathways. Cellular processes that have received attention as being potentially affected by polyQ toxicity include: protein folding, proteasomal degradation, vesicular traffic, mitochondrial energy metabolism and transcription. As pieces of the polyglutamine puzzle fall into place, we are now seeing glimpses of a cellular picture of what is likely to be a complex disease mechanism.
Transcription in Polyglutamine Disease
Evidence is accumulating that dysfunction in transcriptional activation and coactivation may play a central role in polyglutamine pathogenesis [3] . An early and enduring model for pathogenesis is based on the observation that proteins with expanded polyQ tracts have reduced solubility and a propensity to form aggregates with amyloid properties. Such aggregates have been observed in numerous transgenic disease models, and in brain tissue from affected patients. The tendency of expanded polyQ regions to self-associate led to the reasonable expectation that other cellular proteins, particularly those with polyQ tracts, could co-aggregate with the expanded disease proteins, and that loss of function in these cellular proteins might have a role in pathogenesis. This has been referred to as a 'sequestration' model of pathology. Sequestration of a polyQ-containing transcription factor, the TATA-binding protein (TBP), to polyQ inclusions was first demonstrated in spinocerebellar ataxia type-3 disease brain tissue [4] . CAG expansion in the TBP gene itself has now been shown to cause a dominant cerebellar ataxia [5] .
An early indication that histone acetylation dysfunction might be involved in polyQ disease was the observation that CREB-binding protein (CBP), a histone acetyltransferase, aggregates with a protein containing an expanded polyQ tract when the two proteins are co-expressed in cultured cells [6] . The presence of CBP in polyQ aggregates was greatly diminished when a domain containing a polyQ tract was deleted from its carboxyl terminus. At the time, there was no evidence suggesting that CBP function is compromised in polyQ disease.
While the conclusions drawn from this study emphasized the general notion of sequestration of non-expanded polyQ proteins, the choice of CBP as a test case was prescient. It was subsequently shown in cell-culture models that CBP co-localizes in polyQ aggregates of expanded forms of the androgen receptor (mutated in Kennedy disease) and of ataxin-3 (mutated in spinocerebellar ataxia-3) [7] . Importantly, CBP was also localized to nuclear polyQ aggregates in human tissue from a Kennedy disease patient. CBP was similarly localized to aggregates of huntingtinproduct of the Huntington disease gene -in brain tissue of transgenic mice [8] . In human brain tissue from Huntington disease and dentatorubral pallidoluysian atrophy patients, CBP was found to have redistributed from its normal diffuse nuclear localization into polyglutamine aggregates, and levels of soluble CBP were shown to be markedly reduced in brain extracts from Huntington disease patients [9] .
Multiple lines of investigation strongly implicate loss of CBP function as a key cellular defect in polyglutamine disease [10] . The idea that cellular CBP activity may be limiting is supported by the fact that mutation in a single copy of the CBP gene, resulting in loss of histone acetyltransferase activity, causes Rubinstein-Taybi syndrome, a familial disorder characterized by mental retardation and dysmorphic abnormalities [11] . PolyQ expression has been shown to interfere with CBP-mediated transcription and to promote cell death in tissue culture models of Kennedy disease, Huntington disease and dentatorubral pallidoluysian atrophy, and this can be significantly mitigated by overexpression of CBP [7, 9, 12] . Taken together, these data indicate that interaction of expanded polyQ with CBP is involved in the pathogenesis of a diverse group of polyQ diseases and may therefore represent a unifying mechanism for polyQ toxicity. These data also suggest that interventions that augment CBP function could have significant therapeutic benefit (Figure 1 ).
Targets and Therapy
With CBP and the protein acetylation pathway, we may have arrived at a point of having drug targets involved in a primary mechanism of polyQ pathogenesis. The question arises as to how best to translate this knowledge into developing therapeutic interventions. While the success of using CBP overexpression to rescue polyQ toxicity in cell models suggests that a gene therapy approach could be of benefit, it would be preferable to use a small molecule drug that exerted a similar effect. Currently, there are no reports of small molecules that augment histone acetylase function, however there are a number of well characterized histone deacetylase (HDAC) inhibitors (Figure 2) [14] . These authors also demonstrated that polyQ interacts directly with the conserved histone acetyltransferase domain of CBP and the related enzyme P/CAF, and that polyQ directly inhibits acetyltransferase activities in vitro. Direct interaction of polyQ with the active site of these acetyltransferases was a surprising result, demonstrating that inhibition of CBP activity does not require polyQ-polyQ interaction.
In a second study [15] , transcript profiles in a yeast model expressing nuclear-expanded polyQ were found to be similar to those observed with yeast bearing mutations in genes encoding histone acetyltransferase components. PolyQ-mediated repression of the most severely affected gene, PHO84, was mitigated by the HDAC inhibitor trichostatin A (TSA). Finally, in a cell culture model of Kennedy disease, cell death caused by expression of expanded polyQ-containing androgen receptor was reduced by treating the cells with SAHA or TSA [12] .
Because of their ability to promote growth arrest, terminal differentiation and apoptosis in tumor cells, HDAC inhibitors are being investigated as drugs for the treatment of cancer [13] . The anti-proliferative properties of SAHA and related compounds are thought to be due in part to their ability to induce transcription of the gene for p21 WAF1 , a protein important for growth arrest [16] . Intriguingly, a huntingtin fragment containing expanded polyQ was shown to repress transcription from the p21 WAF1 promoter [8] . As the cells affected in the polyQ diseases are primarily non-dividing adult neurons, the benefit of HDAC inhibitors might not be due to their anti-proliferative activity. It is known that expanded polyQ expression leads to repression of many transcripts [15, 17, 18] . Some of these genes may be repressed through mechanisms involving polyQ-mediated effects on protein acetylation. The therapeutic activity of HDAC inhibitors in models of polyQ toxicity could potentially work by restoring levels of key transcripts that encode proteins necessary for neuronal survival.
In moving HDAC inhibitors toward the next stage of evaluation, it will be of great interest to see what effect these compounds have in mouse models of polyQ disease. When using models such as those described here to understand human disease processes, it is important to consider that the natural history of polyglutamine disease is likely to involve significant periods of neuronal dysfunction prior to cell death. Histone deacetylase inhibitors
